TB Alliance’s third license maker makes PretomanID available through the Global Drug Facility, further increasing its affordability and access
The TB Alliance praises new milestones in the fight against drug-resistant tuberculosis (DR-TB). A 25% price reduction in Pretomanid, an important element of BPAL/M regimen. Pretomanid is available for just $169 through Global Drug Facility (GDF), a major pricing benchmark identified by the global TB Advocacy Community, for less than $1 per day. This is less than $1 per day. This latest price drop reflects the ongoing efforts by the TB Alliance and its partners to expand access, expand access and improve affordability, as it falls further from $224 in October 2024, from $364 at the initial approval of Pretomanid in 2019.
TB Alliance, the non-profit organization that developed Pretomanid, has pioneered an innovative access model by partnering with manufacturers that paid multiple quality. This strategy will help launch Pretomanid at early low prices and ensure rapid, sustainable, affordable access to high-TB burden countries. At the same time, by enabling healthy competition and promoting multiple high-quality sources, TB Alliance’s strategy expands availability while reducing costs.
“This advancement shows how thoughtful collaboration and planning can translate into real-world impacts,” said Dr. Mel Spigelman, president and CEO of TB Alliance. “By enabling multiple high-quality producers to supply this drug, we are fostering healthy and sustainable markets to fulfill our mission of adopting, availability and affordable lifesaving drugs we develop. We are grateful for our shared commitment to providing partners such as Lupine and GDF to provide a market that offers lifesavings.
The current GDF price reductions led by Lupine Limited represent an important step in delivering this vision. Procurement via GDF saves an estimated $37 million and allows for the treatment of an additional 120,000 people with DR-TB, according to the STOP TB Partnership, which is responsible for managing GDF.
Along with recent price reductions in other regimen components, the cost of a full BPAL/M treatment course was reduced by $310, less than $2 a day, 47% from the December 2022 price.
BPAL/M is a six-month treatment recommended by the World Health Organization to treat most forms of DR-TB. It consists of bedaquiline (B), prethiminide (PA), and linezolid (L) with or without moxifloxacin (M). In 2024 alone, around 110,000 courses of pretomide have been ordered around the world. This is enough to treat more than 60% of the global market for DR-TB therapy, and is perhaps the fastest scale-up ever for modern new tuberculosis drugs.
“Lupin is proud to work with the TB Alliance and global drug facilities to create Pretomanid in the fight against multidrug resistant TB, which is more accessible and affordable for TB patients around the world.” “Recent price reductions reflect a strong, deep and deep-rooted commitment to providing high-quality, affordable medicines to TB patients around the world. Through this partnership, we must reaffirm our PITIENTINC-centric commitment to innovation and equitable access, and we will need the treatment options needed for countries that are covered by TB, saving lives and strengthening our public health systems.”
“For many years, advocates in the TB community have sought TB treatment that is not only effective, but also affordable for everyone who needs them,” said Olya Klymenko, development director at TB People Ukraine. “Currently, BPAL/M regimens that are under $2 a day make a great deal. We are grateful to everyone who has made this outcome possible. There is no reason why governments and health systems around the world do not offer these treatments to everyone who can benefit from these.”
Sign up for the AllAfrica newsletter for free
Get the latest African news
success!
Almost finished…
You need to check your email address.
Follow the instructions in the email you sent to complete the process.
error!
There was a problem processing the submission. Please try again later.
TB Alliance is still committed to expanding its innovative access model to ensure that new innovations in TB treatment reach everyone who needs it as quickly as possible. With further planned future bids, TB Alliance is looking forward to lowering the ad prices for future Pretomanid. Beyond pricing strategies, TB Alliance continues to develop and implement innovative market access initiatives such as Lift-TB, Slash-TB and Peerlinc Knowledge Hub, speeding up the global uptake, sourcing and implementation of shortened DR-TB therapies for everyone who needs them worldwide.
